While KRAS has been, until recently, seen to be undruggable and the new KRAS inhibitors target only the less frequent mutation G12C [12], several BRAF and MEK kinase inhibitors have been developed and tested also in colon cancer patients. This evidence concerns the gene MAP2K7 and malignant colon neoplasm.